A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
Clinical trial NCT05389449 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05389449
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-28
- Primary completion
- 2026-08-24
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.